Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Hum Pathol

Retrieve available abstracts of 21 articles:
HTML format
Text format



Single Articles


    March 2018
  1. GORDETSKY JB, Schultz L, Porter KK, Nix JW, et al
    Defining the Optimal Method for Reporting Prostate Cancer Grade and Tumor Extent on MR/US Fusion Targeted Biopsies.
    Hum Pathol. 2018 Mar 15. pii: S0046-8177(18)30082.
    PubMed     Text format     Abstract available


    February 2018
  2. CHEN Z, Luo S, Chen Y, Xie X, et al
    High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer.
    Hum Pathol. 2018 Feb 16. pii: S0046-8177(18)30052.
    PubMed     Text format     Abstract available


  3. ERICKSON A, Sandeman K, Lahdensuo K, Nordling S, et al
    New prostate cancer grade grouping system predicts survival after radical prostatectomy.
    Hum Pathol. 2018 Feb 12. pii: S0046-8177(18)30048.
    PubMed     Text format    


    November 2017
  4. ACOSTA AM, Al Rasheed MRH, Rauscher GH, Vormittag E, et al
    Tumor Necrosis in Radical Prostatectomies with High-Grade Prostate Cancer is Associated with Multiple Poor Prognostic Features and a High Prevalence of Residual Disease.
    Hum Pathol. 2017 Nov 24. pii: S0046-8177(17)30434.
    PubMed     Text format     Abstract available


  5. SEIPEL AH, Whitington T, Delahunt B, Samaratunga H, et al
    Genetic profile of ductal adenocarcinoma of the prostate.
    Hum Pathol. 2017;69:1-7.
    PubMed     Text format     Abstract available


    July 2017
  6. TRUONG M, Rais-Bahrami S, Nix JW, Messing EM, et al
    Perineural Invasion by Prostate Cancer on MR/US Fusion Targeted Biopsy is Associated with Extraprostatic Extension and Early Biochemical Recurrence after Radical Prostatectomy.
    Hum Pathol. 2017 Jul 10. pii: S0046-8177(17)30239.
    PubMed     Text format     Abstract available


    June 2017
  7. GILANI S, Guo CC, Li-Ning EM, Pettaway C, et al
    Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
    Hum Pathol. 2017;64:186-190.
    PubMed     Text format     Abstract available


    May 2017
  8. RONEN S, Abbott DW, Kravtsov O, Abdelkader A, et al
    PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
    Hum Pathol. 2017 May 10. pii: S0046-8177(17)30154.
    PubMed     Text format     Abstract available


  9. DE VIVAR AD, Sayeeduddin M, Rowley D, Cubilla A, et al
    Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3).
    Hum Pathol. 2017;63:202-211.
    PubMed     Text format     Abstract available


    March 2017
  10. HAMMERICH KH, Frolov A, Li R, Ittmann M, et al
    Cellular Interactions of The Phosphorylated Form of AKT in Prostate Cancer.
    Hum Pathol. 2017 Mar 11. pii: S0046-8177(17)30065.
    PubMed     Text format     Abstract available


    December 2016
  11. BARAS AS, Nelson JB, Han M, Parwani AV, et al
    The Effect of Limited (Tertiary) Gleason Pattern 5 on the New Prostate Cancer Grade Groups.
    Hum Pathol. 2016 Dec 16. pii: S0046-8177(16)30346.
    PubMed     Text format     Abstract available


    November 2016
  12. FIGIEL S, Vasseur C, Bruyere F, Rozet F, et al
    Clinical significance of epithelial-mesenchymal transition (EMT) markers in prostate cancer.
    Hum Pathol. 2016 Nov 3. pii: S0046-8177(16)30284.
    PubMed     Text format     Abstract available


    June 2016
  13. VOLANTE M, Tota D, Giorcelli J, Bollito E, et al
    Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Hum Pathol. 2016 Jun 21. pii: S0046-8177(16)30119.
    PubMed     Text format     Abstract available


    May 2016
  14. BAUMAN TM, Vezina CM, Ricke EA, Halberg RB, et al
    Expression and colocalization of beta-catenin and lymphoid enhancing factor-1 in prostate cancer progression.
    Hum Pathol. 2016;51:124-33.
    PubMed     Text format     Abstract available


  15. KOSAKA T, Mikami S, Yoshimine S, Miyazaki Y, et al
    The prognostic significance of OCT4 expression in patients with prostate cancer.
    Hum Pathol. 2016;51:1-8.
    PubMed     Text format     Abstract available


    March 2016
  16. PERROUIN VERBE MA, Bruyere F, Rozet F, Vandier C, et al
    Expression of store-operated channel components in prostate cancer: the prognostic paradox.
    Hum Pathol. 2016;49:77-82.
    PubMed     Text format     Abstract available


  17. SADIMIN ET, Ye H, Epstein JI
    Should the involvement of skeletal muscle by prostatic adenocarcinoma be reported on biopsies?
    Hum Pathol. 2016;49:10-4.
    PubMed     Text format     Abstract available


    February 2016
  18. GOLDSTEIN J, Borowsky AD, Goyal R, Roland JT, et al
    Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) in prostate cancer: an immunohistochemical study.
    Hum Pathol. 2016 Feb 4. pii: S0046-8177(16)00035.
    PubMed     Text format     Abstract available


    January 2016
  19. BINGHAM V, Ong CW, James J, Maxwell P, et al
    PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry.
    Hum Pathol. 2016;47:95-103.
    PubMed     Text format     Abstract available


    November 2015
  20. BAUMAN TM, Becka AJ, Sehgal PD, Huang W, et al
    SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-kappaB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Hum Pathol. 2015;46:1744-51.
    PubMed     Text format     Abstract available


    October 2015
  21. PUST A, Kylies D, Hube-Magg C, Kluth M, et al
    Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Hum Pathol. 2015 Oct 22. pii: S0046-8177(15)00388.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: